靶向GRPR的前列腺癌分子影像与治疗新型放射性示踪剂
本研究合成并评估了新型铃蟾肽衍生物ProBOMB2,分别用68Ga和177Lu标记,在PC-3人前列腺癌荷瘤小鼠模型中验证其靶向胃泌素释放肽受体(GRPR)的能力。结果显示两种示踪剂标记纯度均大于95%,主要经肾脏排泄,68Ga-ProBOMB2 PET显像肿瘤对比度良好且脱靶器官摄取低,177Lu-ProBOMB2 SPECT显像可清晰显示肿瘤,提示其在前列腺癌GRPR表达肿瘤的成像与治疗中具有前景。
要点
- 68Ga-ProBOMB2与177Lu-ProBOMB2对PC-3细胞的抑制常数分别为4.58±0.67和7.29±1.73 nM。
- 两种示踪剂放射化学纯度均大于95%,主要经肾脏排泄,胰腺摄取有限。
- 177Lu-ProBOMB2在注射后1、4、24小时的肿瘤摄取分别为14.9±3.1、4.8±2.1、1.7±0.3 %ID/g。
核心结论
- 68Ga-ProBOMB2和177Lu-ProBOMB2是靶向GRPR表达肿瘤的候选放射性示踪剂,具有胰腺摄取有限、肿瘤摄取良好及药代动力学有利的特点。
研究设计与样本
- 临床前研究,采用固相Fmoc化学合成ProBOMB2,以DOTA为螯合剂并通过阳离子4-氨基-(1-羧甲基)-哌啶间隔臂与GRPR靶向序列连接。
- 用细胞竞争实验测定对人及鼠GRPR的结合亲和力,用钙流出实验评估激动/拮抗特性。
- 在携带GRPR阳性PC-3人前列腺癌异种移植瘤的雄性免疫缺陷小鼠中进行SPECT和PET显像及生物分布研究。
主要发现
- Ga-ProBOMB2和Lu-ProBOMB2与PC-3细胞结合的抑制常数分别为4.58±0.67和7.29±1.73 nM。
- 68Ga-ProBOMB2和177Lu-ProBOMB2的放射化学纯度均大于95%,两者主要经肾脏途径排泄。
- 注射68Ga-ProBOMB2后1和2小时PET显像可清晰显示PC-3肿瘤,对比度极好,脱靶器官蓄积很低。
- 注射177Lu-ProBOMB2后1、4和24小时SPECT显像均可清晰显示PC-3肿瘤,且注射后1小时肿瘤摄取高于68Ga-ProBOMB2。
- 177Lu-ProBOMB2注射后1、4、24小时的肿瘤摄取分别为14.9±3.1、4.8±2.1、1.7±0.3 %ID/g。
临床怎么用
- 68Ga-ProBOMB2可用于GRPR阳性前列腺癌的PET显像,177Lu-ProBOMB2可用于SPECT显像及潜在靶向治疗。
- 胰腺摄取有限的特点可能有助于减少GRPR靶向显像与治疗中的脱靶效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The gastrin-releasing peptide receptor (GRPR) is overexpressed in many solid malignancies, particularly in prostate and breast cancers, among others. We synthesized ProBOMB2, a novel bombesin derivative radiolabeled with 68Ga and 177Lu, and evaluated its ability to target GRPR in a preclinical model of human prostate cancer. Methods: ProBOMB2 was synthesized in solid phase using fluorenylmethoxycarbonyl chemistry. The chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid was coupled to the N terminus and separated from the GRPR-targeting sequence by a cationic 4-amino-(1-carboxymethyl)-piperidine spacer. Binding affinity for both human and murine GRPR was determined using a cell-based competition assay, whereas a calcium efflux assay was used to measure the agonist and antagonist properties of the derivatives. ProBOMB2 was radiolabeled with 177Lu and 68Ga. SPECT and PET imaging and biodistribution studies were conducted using male immunocompromised mice bearing GRPR-positive PC-3 human prostate cancer xenografts. Results: Ga-ProBOMB2 and Lu-ProBOMB2 bound to PC-3 cells with an inhibition constant of 4.58 ± 0.67 and 7.29 ± 1.73 nM, respectively. 68Ga-ProBOMB2 and 177Lu-ProBOMB2 were radiolabeled with a radiochemical purity greater than 95%. Both radiotracers were excreted primarily via the renal pathway. PET images of PC-3 tumor xenografts were visualized with excellent contrast at 1 and 2 h after injection with 68Ga-ProBOMB2, and there was very low off-target organ accumulation. 177Lu-ProBOMB2 enabled clear visualization of PC-3 tumor xenografts by SPECT imaging at 1, 4, and 24 h after injection 177Lu-ProBOMB2 displayed higher tumor uptake than 68Ga-ProBOMB2 at 1 h after injection. 177Lu-ProBOMB2 tumor uptake at 1, 4, and 24 h after injection was 14.9 ± 3.1, 4.8 ± 2.1, and 1.7 ± 0.3 percentage injected dose per gram of tissue, respectively. Conclusion: 68Ga-ProBOMB2 and 177Lu-ProBOMB2 are promising radiotracers with limited pancreas uptake, good tumor uptake, and favorable pharmacokinetics for imaging and therapy of GRPR-expressing tumors.
引用
- Bratanovic IJ, Zhang C, Zhang Z, et al. A Radiotracer for Molecular Imaging and Therapy of Gastrin-Releasing Peptide Receptor-Positive Prostate Cancer. J Nucl Med. 2021. PMID: 34301778. doi:10.2967/jnumed.120.257758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。